Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang · 2026
Read Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study by Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585213.txt.
Description
Two drugs paired as first care for a hard lung cancer form are tested by Xiaojun Yang and co-authors in work dated 2026. The cancer carries a growth switch flaw plus extra flaws in genes like TP53. Such extra flaws speed drug failure, so one drug alone fades fast. Thirty-eight patients across sites took the pair, with blood tests before and after.
Tumors shrank in near three of four patients, and all held at least steady. Mid time before spread ran near twenty-nine months. Harsh side effects hit under a fifth of patients, with no drug deaths. The pair looks strong and safe enough to test more.
Catalog record
| CREATOR | Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |